12.12.11
Bioscreen Clinical Services' safety & efficacy testing RIPT panel begins on Dec. 19. The RIPT test is the industry standard safety testto determine the potential for skin sensitization and allergy development in a product.
Upon completion of the Repeat Insult Patch Test the following claims may be valid after meeting certain criteria:
• Non-Irritating
• Clinically Tested
• Allergy Tested
If no allergenic reactions are observed, optional dermatologist involvement in study allows for"Dermatologist reviewed" claim.
BioScreen's next panel begins Dec. 19, 2011. All samples need to be submitted to BioScreen by Dec. 16, 2011. More info: 310-214-0043 orinfo@bioscreen.com
Upon completion of the Repeat Insult Patch Test the following claims may be valid after meeting certain criteria:
• Non-Irritating
• Clinically Tested
• Allergy Tested
If no allergenic reactions are observed, optional dermatologist involvement in study allows for"Dermatologist reviewed" claim.
BioScreen's next panel begins Dec. 19, 2011. All samples need to be submitted to BioScreen by Dec. 16, 2011. More info: 310-214-0043 orinfo@bioscreen.com